Today at Ms. | January 22, 2026 |
|
|
With Today at Ms.—a daily newsletter from the team here at Ms. magazine—our top stories are delivered straight to your inbox every afternoon, so you’ll be informed and ready to fight back. |
|
|
(Frederic J. Brown / AFP via Getty Images) |
By David S. Cohen and Carole Joffe | Now, almost three and a half years after the Supreme Court overturned Roe v. Wade, the numbers are clear that abortion in the United States has, to the shock of most, continued to rise. But we also have data showing that a small but not trivial number of people are continuing their pregnancies to birth due to abortion bans. To us, what this shows is clear: that overturning Roe has prompted ingenuity, persistence and resistance among providers and patients, but is also leaving many people behind. Ultimately, this is no way to deliver healthcare.
(Click here to read more) |
|
|
(Ronen Tivony / NurPhoto via Getty Images) |
By Kierra Jones | With the 2026 Affordable Care Act (ACA) open enrollment period now closed, millions of Americans are facing an uncomfortable new reality: higher monthly costs for the health coverage they already struggled to afford.
Because congressional Republicans failed to extend the ACA’s enhanced premium tax credits, they expired at the end of 2025 and triggered the return of a catastrophic “subsidy cliff.” Since 2021, these credits have helped millions of Americans, especially women, afford their monthly premiums. In fact, in the first year of the enhanced tax credits, women’s enrollment in the ACA Marketplace increased more than 18 percent from around 6.5 million to 7.8 million, and by 2025, women’s enrollment reached nearly 12.7 million.
(Click here to read more) |
|
|
By Carrie N. Baker | The story of mifepristone and fibroids is not an isolated case—it is a pattern. Across a range of conditions that disproportionately affect women, research into the drug’s potential has been slowed, defunded or blocked altogether. Nowhere is that clearer than in the treatment of endometriosis and other serious illnesses that leave millions of women in chronic pain.
(Click here to read more) |
|
|
|
Tune in for a new episode of Ms. magazine's podcast, On the Issues with Michele Goodwin, at MsMagazine.com, Apple Podcasts or wherever you listen to podcasts.
Welcome to “The Magazine,” our mini-pod, which gives a peek into Ms. magazine’s forthcoming and current issues. In this episode, take a glimpse inside our Winter 2026 issue, which delves into the promise and potential of the abortion medication Mifepristone—which has been shown to treat a striking range of diseases and conditions including fibroids, breast cancer, depression, endometriosis and more. Also in the Winter issue: Jess Michaels on surviving Epstein, the Iceland “Women’s Strike” turns 50, and more.
We hope you'll listen, subscribe, rate and review today! |
|
|
Enjoy this newsletter? Forward to a friend!
Was this email forwarded to you by a friend? Subscribe. |
|
|
Ms. Magazine
1600 Wilson Boulevard
Suite 801
Arlington, VA 22209
United States
Manage your email subscriptions here
If you believe you received this message in error or wish to no longer receive email from us, please unsubscribe. |
|
|
|
